Shandong Boan Biotechnology Co., Ltd. (Boan Biotech) disclosed a Next Day Disclosure Return showing an on-market repurchase of 300,000 H shares on 17 September 2026.

The buy-back was executed at prices between HKD 2.47 and HKD 2.585, resulting in a volume-weighted average cost of HKD 2.5505 per share and a total cash outlay of HKD 0.77 million. All repurchased shares were retained as treasury stock; none were cancelled.

Following the transaction, issued shares outstanding (excluding treasury shares) fell by 0.05 % to 613.63 million, while treasury shares rose to 8.70 million. Total issued share capital remained unchanged at 622.33 million shares.

The repurchase forms part of the mandate approved on 22 June 2026, which authorises buy-backs of up to 62.23 million shares. To date, Boan Biotech has repurchased 8.70 million shares under this authority, equal to 1.40 % of the company’s issued shares on the mandate date. A moratorium on new share issues or the sale of treasury shares is in effect until 17 October 2026.